Both inhaler therapies were developed by GSK The prevalence is higher among those who are 75 years of age and older Trelegy contains three medications: fluticasone umeclidinium and vilanterol delivered through a once-a-day inhaler Breo contains two medications: fluticasone and vilanterol delivered through a once-a-day inhaler Both are approved to treat COPD and asthma From November 2023 to October 2024, total Medicare Part D costs for Trelegy Ellipta were $5.1 billion, and total Medicare Part D costs for Breo Ellipta were $1.4 billion, according to CMS ICER evaluated the evidence of the two COPD treatments and plans to send the public comment submission to CMS as part of its work on Medicare drug price negotiations ICER reviewers found that comparators for Trelegy Ellipta generally require multiple inhalers administered twice daily and for Breo Ellipta generally require at least one inhaler twice daily Observational data suggest that patients are more adherent to once-daily therapy and this may lead to fewer COPD exacerbations “The drugs themselves don’t make a big difference,” David M there is huge nonadherence and discontinuation in COPD More than half of people stop using them because they don’t feel better right away when they use the inhalers so they tend to keep using them; not so much in COPD.” But Rind said nonadherence is difficult to measure in clinical trials so ICER assessed observational and real-world studies Because the clinical evidence review used observational data meaning there was comparable or incremental net health benefit compared with generic dual therapies ICER evaluated Trelegy and Breo based on 20 different comparator prices across a range of willingness-to-pay thresholds “We don’t know the actual prices that CMS is paying for those comparators,” ICER’s President and CEO Sarah K “We have some data about what it might cost for the comparators for both Trelegy and Breo And we also don’t know what CMS is currently paying for Trelegy and Breo We have some general estimates of the rebates that they might be getting.” The report contains tables that could help CMS determine the cost-effectiveness based on what it pays for each therapy and assess that on equal value of life year (evLY) The evLY is an ICER-developed measure of quality of life that equitably captures improvements in quality of life for patients due to a new treatment allowing for a fair comparison of the value of new drugs compared with older ones CMS decided not to use the quality adjust life year (QALY) metric a standard measurement for how a treatment improves patients’ lives The QALY metric has become a standard way to assess health economics but has been criticized as discriminatory “The limitations of the QALY metric led us to develop the equal value of life years gained metric,” Emond said “The evLY values all the time and the life extension the same no matter if you have other chronic conditions or other disabilities other than the ones being studied We’re proud of developing a metric that meets the goals of having a more equitable way to measure health gain and that's why it's our primary measure and the only measure we used for this special assessment.” FDA Sets Action Date for Oral Wegovy for Weight Loss FDA Approves Imaavy for Long Term Treatment of Generalized Myasthenia Gravis Adult and pediatric generalized myasthenia gravis patients have a new longer acting option for treatment called Imaavy CVS Caremark to Place Wegovy as Preferred GLP-1 for Weight Loss CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies Oncologists: Prior Authorizations Lead to Delays in Getting Cancer Meds Insurance hurdles and the complexities of prior authorization create barriers to care according to oncologists in a new survey by Sermo Novo Nordisk Offers Wegovy Through Telehealth Providers, Including Hims & Hers Food Retailer Giant Eagle Selects EmpiRx Health as PBM Giant Eagle also helped EmpiRx Health create a national pharmacy care network that was purpose-built for pharmacy and grocery chains 609-716-7777 is set to release their debut album Máis Alá on Wednesday The album features ten tracks inspired by Galician mysticism the album includes collaborations with various artists such as singer Sabu l’Aviseu on Canto Raibas and the Triskell Cultural Association band from Arteixo on Os Lombois The group’s name is derived from the Celtic deity Berobreo the guardian of souls tasked with guiding them to the afterlife Berobreo’s sanctuary is located atop Monte do Facho in Donón one of the legendary Atlantic ends of the world in Western Europe The band members in 2024 included Sandra Novais Meireles on vocals and tambourine; Samuel Lafuente Carballeda on violin; Rubén Gómez Castro on guitars; Migui Ocampo on bodhran and programming; and Bieito Romero Diéguez on flute Please enter an answer in digits:1 × 5 = The fall session of the Health Sciences Fellowship Workshop is now open. Sign up now! Open to students who have passed their preliminary exams and who are applying for a NIH fellowship for the December 2024 deadline. Email: BREO@hsc.utah.edu to sign up The Biomedical Research Education Office (BREO) offers the Health Sciences Fellowship Workshop to PhD Graduate Students with the purpose to provide support to submit a strong fellowship application to NIH This workshop is not intended to be a grant writing course focused on articulating a scientific idea but rather a workshop to help guide students toward a specific submission deadline The Food and Drug Administration (FDA) has expanded the approval of Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) to include maintenance treatment of asthma in children 5 to 17 years of age the product was only approved for maintenance treatment of asthma in adults Patients aged 12 to 17 years were randomly assigned to receive Breo Ellipta 100/25mcg once daily (n=117) or fluticasone furoate 100mcg once daily (n=112) Participants aged 5 to 11 years were randomly assigned to receive Breo Ellipta 50/25 mcg once daily (n=337) or fluticasone furoate 50mcg once daily (n=336) The primary endpoint of the study was the weighted mean of forced expiratory volume in 1 second (FEV1) (0 to 4 hours) at week 12 Results showed that among patients 12 to 17 years of age the difference in least squares (LS) mean change in FEV1 (0 to 4 hours) for Breo Ellipta 100/25mcg compared with fluticasone furoate 100mcg was 106mL (95% CI the difference in LS mean change in FEV1 (0 to 4 hours) for Breo Ellipta 50/25mcg compared with fluticasone furoate 50mcg was 73mL (95% CI adverse reactions reported in at least 3% of pediatric patients treated with Breo Ellipta were nasopharyngitis (10%) Breo Ellipta is supplied as a disposable light grey and pale blue plastic inhaler containing 2 foil strips In addition to the 100/25mcg and 200/25mcg dosage strengths the FDA has approved a new 50mcg/25mcg dosage strength for pediatric patients aged 5 to 11 years a trusted source of medical news and feature content for healthcare providers offers clinicians insight into the latest research to inform clinical practice and improve patient outcomes Copyright © 2025 Haymarket Media, Inc. All Rights Reserved. This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions. Only subscribers can update their account from this page You’ve read {{metering-count}} of {{metering-total}} articles this month We want you to take advantage of everything MPR has to offer Register now at no charge to access unlimited daily drug news and industry-supported drug information & education Please login or register first to view this content For Plant LoversHorti Plant SubscriptionRead more For the Old-School Music FanVinyl Me, Please SubscriptionRead more For KidsKiwiCo Kiwi CrateRead more For the WIRED OnesBreo Box SubscriptionRead more Don't throw your hands in the air yet—consider a subscription box and your giftee can try a bunch of stuff that would be far too expensive for you to compile yourself but I think three months makes the perfect gift since they'll get that warm I'm also a firm believer that you need to gift yourself every so often These boxes work whether you're buying for yourself or someone else WIRED Gear writers hand-tested every one of these recommendations Be sure to check out our many other gift guides, like Gifts for Teens and 25 Gifts Under $25, and some of our favorite gifts, like this tiny TV. Updated November 2024: We've removed four older picks and added a hot sauce box, a meat box, a beauty box, and a giftable meal kit. We also updated pricing throughout. but they're already halfway dead by the time they get to your giftee plants are fantastic gifts that can live on for years if cared for correctly Horti makes it easy for someone to slowly turn their living quarters into a jungle Price breakdown: Starting at $36 per month, $155 for three months, or $310 for six months. (All cost a few dollars more for a painted pot, or less if you can pick it up in NYC.) Prices don't include shipping. Vinyl Me, Please sends an exclusively pressed record every month to those who can't get enough of that old-school sound Members can swap that month's pick for another title in their catalog if they'd prefer Price breakdown: $54 per month, $149 for three months, $279 for six months, $529 for 12 months. Gift-specific options cost the same, but don't auto-renew and are available for three, six, or 12 months. but after a while they end up in the pile that go unused We think a subscription box like this is a better option to give them interesting hands-on activities that they'll enjoy (and hopefully learn from in the process!) WIRED reviewer Adrienne So has watched her kids make everything from water guns to kaleidoscopes; she said there was even a night-themed box where everything glowed Price breakdown: Kiwi Crates start at $24 a month and different clubs have additional subscriptions that vary by club If you don't want to worry about canceling you can purchase the same amount of boxes for a few dollars more (You'll see the option for non-renewing during the selection process.) Shipping is free in the US Crates for older kids are a bit more expensive ★ More options: We have many more favorite subscription boxes for kids if you don't think this one is right. We've tried other craft boxes, book subscriptions, and even coding kits. Never know what to get your nerdy younger brother filled with four to eight of the latest gadgets and gizmos It's the priciest option on this list and your giftee may get some things they don't particularly have use for but that's a possibility with any subscription box This one at least gets curious hands on some cool tech Price breakdown: Vellabox starts at $12, $22, and $29 a month depending on candle size and subscription length—4, 8, and 16 ounces respectively; $90, $150, and $204 for six months; and $144, $264, and $348 for 12 months. There are single-orders and auto-renewing options. Shipping is free in the US. Photograph: Conscious StepConscious Step There's nothing quite as nice as hearing my coffee pot sizzle from the kitchen as I'm getting up in the morning knowing a nice warm mug is just minutes away or just wants to break out of their Starbucks addiction opt for a coffee subscription to broaden their horizons We like Misto for gifts because there are nearly 500 types of beans to choose from ★ Alternative: We have many more coffee subscription options to choose from, including one-off gift options. Traveling all over the world and learning about different cultures is a dream that's not always doable For those who can't hop on a plane at a moment's notice the Undiscovered Artisan Box offers a look at a specific region through handmade goodies delivered to their door subscribers can either choose or be surprised with five gifts that include ethically handmade home goods and other accessories—the Thailand box included a singing bowl Price breakdown: $60 every three months. $4 shipping added. Photograph: Universal YumsUniversal Yums Who among us doesn't like to snack on delicious treats all day between meetings The Universal Yums box is our favorite snack box and it includes food from a different country each month plus a booklet with trivia and games on the country so you get a little learning opportunity as well Price breakdown: Small boxes (five to seven snacks): $19 per month or $204 upfront for a year Medium boxes (10 to 12 snacks): $29 per month or $312 for a year Large boxes (15 to 18 snacks): $40 per month or $480 for a year ★ More options: We also have more snack options for jerky and Japanese snack lovers, plus those who want more customizable quantities. I love bringing a nice bottle of wine to someone's house as a gift but from there I have no idea what to look for I often think about the line in The Devil Wears Prada where Emily talks about her insane new diet: “When I feel like I'm about to faint, I eat a cube of cheese.” I'm not on board with a starvation diet, but I am on board with eating cubes of cheese throughout the day. Snacks, meals, sides? Just say cheese. A Curdbox subscription includes three blocks of cheese, plus three snack pairings wrapped in ice blocks to keep it all good (similar to a meal kit). Each box even includes a Spotify playlist, blog post, and wine-pairing suggestions. —Medea Giordano Price breakdown: $85 per month, $246 for three months, $489 for six months. Gift options include three and six months for the same price, plus $972 for 12 months that don't auto-renew. Shipping is free. Photograph: Book of the MonthBook of the Month There is nothing quite like wandering the aisles of a bookstore or library but that's not always possible in our busy lives If someone on your gift list always has their head in a book or has mentioned they want to read more you can sign them up for a Book of the Month subscription Each month there are five to seven new books to choose from The base subscription cost covers one book If none strike their interests or they're still reading last month's book Bespoke Post has options for everyone, but I think it's a great place to start for men who are hard to buy for. If you've ever searched for men's gifts, guides typically include stereotypical things like whiskey stones and meat. Bespoke has a lot more variation and every month includes different options. First you'll take a short quiz for your giftee—the questions are easy enough for you to guess (would they like kitchenware, clothes, cigars?)—then each month a box is assigned based on those interests. You can view and swap boxes before it ships (or skip it for the month). You can even choose the first box and then give your giftee the login info so they can choose from there. —Medea Giordano Price breakdown: $49 per box plus $5 shipping. If you don't want to auto-renew, a single box costs $70. If you don't gift your pet something on holidays, then we can't be friends. They're family too! Thankfully, they can also get a subscription box. We've tried Meowbox and Barkbox and loved them both for our cats and dogs Typically there's a mix of samples and full-size products plus every box has exclusive discounts in case your giftee feels inspired to go shopping after trying out their new goodies Members also have access to an exclusive Member Shop with savings on beauty must-haves I especially liked the trio of lip products in mine—a lipstick and a gloss—and while contents vary from box to box your giftee will probably like what they receive too Alternative: We have many more beauty box subscription recommendations, including options for only full-size products and options that can be customized. This ultra-giftable gourmet box comes with premium It's more expensive than some other meat boxes but the contents of each box are special and elevated—something that's arguably difficult to achieve when you're mailing a box of meat hunks to a loved one WIRED reviewer Adrienne So tested this box and received two perfectly marbled New York strip steaks and the delicious result after cooking them still visits her in her dreams Alternative: Check out our guide for additional meat subscription box recommendations that are more affordable or more specific. There are also varying levels to the subscriptions that can be tailored to your giftee's taste buds WIRED contributor Andrew Watman was delighted by That's What Shishito Said a sweetly balanced shishito-based hot sauce that was as tasty as it was unconventional Each box will contain at least one hot sauce that's unique and (probably) not readily available at your giftee's local grocery store Price breakdown: $13 per box for one sauce in each box (shipped monthly) $30 per box for three hot sauces in each box (shipped monthly or every three months) or $29 per box for the “Pain Seeker” subscription which includes two extra-hot sauces (shipped monthly or every three months) Alternative: For additional sauce box recommendations, check out our guide to the Best Barbecue Sauce, Rub, and Hot Sauce Subscription Boxes. Photograph: Louryn StrampeCook with Bon Appétit The Cook With Bon Appétit box isn't your typical meal kit each box includes five exclusive recipe cards and five shelf-stable ingredients from each of those recipes The first box also includes a little binder where your giftee can store their recipe cards If you want to gift them something to aid their time in the kitchen but you don't want to go with a typical countertop appliance or another gadget they might already own this is a solid option—especially if they're an avid reader of the magazine as this comes with digital subscriptions to Epicurious and Bon Appétit as well from pure chocolate ecstasy to bundles of fun.Matthew KorfhageWired CouponsWayfair Coupons10% Off Wayfair Promo Code with sign-up $50 Off In-Person Tax Prep When You Switch From Your Tax Current Provider Exclusive: Up To 50% Off 6 Boxes With Factor Promo Code It is the essential source of information and ideas that make sense of a world in constant transformation The WIRED conversation illuminates how technology is changing every aspect of our lives—from culture to business The breakthroughs and innovations that we uncover lead to new ways of thinking Become a navigator of the tobacco cessation process through this free Read our simple and effective tips for protecting you and your family from the dangers of air pollution Our key findings add to the evidence that a changing climate is making it harder to protect human health Share your voice and advocate for policies that will save lives Step up for lung health by participating in a Fight For Air Climb event near you Matching gifts are a great way to stretch your donation as well as voluntary commitments from pharmaceutical manufacturers have helped to reduce the cost of insulin for people with diabetes and many stakeholders have now turned their attention to reducing the cost of inhalers for patients with asthma Read more about these recent changes and how they may impact the cost of your inhaler.  which applies to inhalers for asthma and other lung diseases is awaiting the Governor’s signature and would take effect in January 2026.  At the federal level, senators on the Senate Health, Labor and Pensions (HELP) Committee launched an investigation into the price of asthma inhalers in January 2024 There are also several bills at different stages of the legislative process in the U.S House and Senate that would change the practices of pharmacy benefit managers (PBMs) that could impact the cost of inhalers as well as other medications for the treatment of chronic conditions like lung disease.  three companies announced new voluntary programs to reduce and cap the cost of their inhalers to $35 or less per month.  It is important to note that patients with government insurance are not eligible for these discounts.  While an FDA approved Authorized Generic is now available it will not be part of this program.  Navigating your options to reduce the cost of your inhaler can be challenging. If you still have questions about the cost of your inhaler, you can reach out to the American Lung Association’s Lung HelpLine for assistance Our trained Lung Health Navigators also offer free one-on-one education programs to support those living with lung disease including COPD and asthma Learn more at Lung.org/Navigator or call 1-866-252-2959.  Your gift will help people with asthma breathe easier—at school Donate now Join over 700,000 people who receive the latest news about lung health The American Lung Association is a 501(c)(3) charitable organization This website uses cookies to improve content delivery Talk to our lung health experts at the American Lung Association Our service is free and we are here to help you Lohit Khera discusses the evolving role of microRNA in research highlighting the latest innovations in RNA extraction and analysis Learn how experts are advancing benzodiazepine analysis and detection using insights from the lab discusses how he is addressing today’s medical challenges using the technology of the future you can trust me to find commercial scientific answers from News-Medical.net please log into your AZoProfile account first Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content A few things you need to know before we start Read the full Terms & Conditions Newsletters and Deep Dive digital magazine The list for the next round of medicines that will be subject to Medicare price negotiations isn’t in yet but the Institute for Clinical and Economic Review (ICER) reckons a chronic obstructive pulmonary disease (COPD) drug will be included – and is preparing to contribute to the process it has decided to publish a special report on two of GSK's COPD therapies – Breo Ellipta (fluticasone furoate and vilanterol) and Trelegy Ellipta (fluticasone furoate and vilanterol) – saying that it has "the expectation that at least one of the drugs being reviewed will be subject to negotiation next year." The Centers for Medicare & Medicaid Services (CMS) has said it will announce the next 15 drugs in scope for the second round of the Medicare negotiation programme by 1st February next year with the negotiated prices due to be announced by 30th November and coming into effect on 1st January 2027 "As CMS continues to evolve its drug price negotiation programme we will continue to bring our expertise in comparative clinical effectiveness and value to the conversation," said ICER's president and chief executive "While we know CMS may consider many different factors and inputs during negotiations we believe applying the guidance in a consistent framework as we did with our special assessment of two drugs subject to the first round of negotiation offers important information to all stakeholders engaged in this process." ICER has published the research protocol (PDF) for the evaluation of Breo Ellipta and Trelegy Ellipta – which made £1.1 billion (almost $1.5 billion) and £2.2 billion for GSK last year and are two of the company's biggest products – and expects to publish the special report later this year It plans to estimate the "comparative therapeutic impact" of the two drugs compared to their respective fixed-dose generic alternatives or open generic combinations in patients with moderate to severe COPD attempts by the industry to strike down the price negotiation programme in the courts have proved fruitless and the first round resulted saw 10 big-selling medicines have their prices reduced by between 38% and 79% with the Biden administration claiming that would save $6 billion in 2026 It's been well recorded that the true impact of the programme is hard to gauge. For more on the potential consequences and next steps, you can tune into our recent podcast with pharmaphorum editor-in-chief Jonah Comstock and healthcare policy expert Alice Valder Curran of Hogan Lovells The Trump administration has intervened in a long-running lawsuit over the abortion pill mifepristone Jonah Comstock welcomed back Alice Valder Curran to the podcast to pick apart Trump's Executive Order order piece by piece Understanding how to harness real-world data and digital insights is essential The importance of biosimilars only continues to grow driven by the potential savings they are able to deliver to healthcare systems Web editor Nicole Raleigh speaks with Rob Abbott Developments in the oncology space in 2024 brought hope to both industry and patients The ESG in Life Sciences Summit West is coming to San Francisco The ISPE Singapore Affiliate Conference & Exhibition is one of the largest and most respected events for bio & pharmaceutical manufacturing professionals opinions and features on pharma and healthcare sent straight to your inbox on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET entitled ‘Health Trends 2025: Reimagining What's Possibl Sign up for email newsletters and Deep Dive Offering 3 levels of intelligent air pressure improving blood circulation as well as relieving your hands and fingers Furthermore, the massage dots on it provide a full hand and finger massage it improves microcirculation and helps your hands feel less strained and tense One of the best parts is that it has heating from 98 to 107 ºF to promote blood flow this portable gadget is one you’ll want to take everywhere to ensure your hands feel great Whether you type at a computer all day or perform other repetitive tasks We use cookies to personalize your experience. Learn more here ' + scriptOptions._localizedStrings.webview_notification_text + ' " + scriptOptions._localizedStrings.redirect_overlay_title + " " + scriptOptions._localizedStrings.redirect_overlay_text + " Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) is a dry powder inhaler indicated for the long-term maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD) Breo Ellipta / fluticasone furoate and vilanterol inhalation powder Combination of inhaled corticosteroid (ICS) and long-acting beta2 agonist (LABA) Chronic obstructive pulmonary disease (COPD) Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) is a dry powder inhaler indicated for the long-term maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD) The drug was developed by GlaxoSmithKline (GSK) in collaboration with Theravance Breo Ellipta was approved by the US Food and Drug Administration (FDA) in May 2013 for the treatment of airflow obstruction in patients with COPD Health Canada also approved the drug for the treatment of COPD patients in July 2013 The drug received approval from the Japanese Ministry of Health Labour and Welfare (MHLW) for the treatment of bronchial asthma in September 2013 It has received a positive response from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for the treatment of COPD patients in September 2013 The final approval from EMA is expected to be received by the end of 2013 Breo Ellipta is marketed under the trade name Relvar Ellipta in Europe and Japan Chronic obstructive pulmonary disease (COPD) is a lung disease that restricts the flow of air to and from the lungs which involves a long-term cough with mucus Most of the patients affected by COPD have a blend of both forms of the disease The main cause of the disease is tobacco smoking COPD is estimated to affect about 27 million people in the US Breo Ellipta contains two drug combinations Fluticasone furoate is an inhaled corticosteroid (ICS) and vilanterol is a long-acting beta2 agonist (LABA) The drug helps breathing by reducing the risk of future exacerbations with a once-daily inhalation The drug is available in new dry powder inhaler (DPI) form which contains 100µg of fluticasone furoate and 25µg of vilanterol The FDA approval for Breo Ellipta was based on 52 clinical pharmacology studies conducted on 1,406 patients and 11 clinical studies conducted on 7,851 patients with COPD The clinical studies included four primary COPD studies two six-month lung-function studies and two one-year replicate exacerbation studies GSK conducted a Phase I clinical trial on Breo Ellipta between December 2011 and March 2012 crossover assignment enrolled 30 patients with COPD The primary outcome measure of the study was finding the pharmacokinetic parameters for fluticasone furoate (FF) for all study participants between pre-dose and 36 hours post-dose in each of the six treatment periods The secondary outcome measure included finding the adverse events (AEs) for all participants in the study GSK conducted a Phase III clinical trial on Breo Ellipta between February 2011 and October 2011 The study enrolled 531 patients aged 40 years and above The primary outcome measure of the study was finding the change from baseline trough in 24-hour weighted-mean serial FEV1 on day 84 The secondary outcome measures included finding time to onset Breo Ellipta was launched in the US market in 2013 The other medications approved for the treatment of the same indication include Tudorza Pressair developed by Forest Laboratories and Almirall and Spiriva developed by Boehringer Ingelheim and Pfizer GSK entered into an agreement with Theravance for the development of and commercialisation of long-acting beta2 agonist (LABA) products in November 2002 both the companies entered into a strategic alliance for development and commercialisation of different therapeutic areas which gave an option for GSK to license exclusive development and commercialisation rights of the product candidates from certain of Theravance’s discovery programs GSK licensed MABA program of Theravance for the treatment of COPD in 2005 Theravance entered into an agreement with Elan Corporation in May 2013 as per which Elan will pay $1bn royalty payment to Theravance for offering 21% participation interest in potential future royalty payments associated with four respiratory programs that Theravance partners with GSK Anoro ellipta (umeclidinium bromide / vilanterol) is a dry powder for inhalation indicated for the treatment of airflow obstructions in patients suffering from Chronic Obstructive Pulmonary Disease (COPD) or emphysema Adempas (riociguat) is indicated for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Give your business an edge with our leading industry insights View all newsletters from across the GlobalData Media network My life feels like it’s go-go-go a lot of the time, and it’s tough to find moments to unwind. Even if I can relax a bit, I can’t always ease the tension in my neck and shoulders. That’s why I was excited to receive this gadget to test out. Keep reading to for my Breo N5 Mini hands-on review The Breo N5 Mini is a handheld massager designed to target your most troublesome stress points with precision and ease Its sleek design and ergonomic build make it a delightful companion for anyone seeking a quick escape from the daily grind or a soothing recovery from a strenuous workout At least that’s what the brand says—but does the Breo N5 Mini live up it I dive deep into every aspect of the Breo N5 Mini my hands-on review is an honest assessment of the Breo N5 Mini If you want to know if it’s the right fit for you I wasn’t sure what to expect when I received the box and I didn’t think a full-on neck massager could fit in there it has an integrated carry handle that makes it easy to transport That’s if you like to keep things in their packaging on the go The Breo N5 Mini comes with a user manual and a USB charging cable. I appreciated that there wasn’t a bunch of extra packing material in the box. Less waste is a win in my book and fairly lightweight this personal massager is which also makes it easy to fit around your neck it has a normal amount of heft to it that you’d expect from a massager matte finish—I received the grey color option—that gives it an enjoyable tactile feel but the matte finish also makes it easy to grip the N5 Mini would be pretty easy to take on the go I could easily see myself packing this in a bag for a weekend getaway Can’t say I’d take it in a suitcase for a flight this massager is certainly durable with a solid body that feels sturdy in my hand It definitely seems like a massager that would last for years of use Thanks to the Breo N5 Mini’s ergonomic design it’s comfortable to wear for the recommended 10-minute massage period It fit snugly around my neck and shoulders and the lightweight design didn’t cause any discomfort or strain The higher intensity was a bit much for me One feels more like a rolling massage you’d expect from another person I left it on and loved the feeling of heat on my neck It truly helped reduce the effects of all-day tightness in my neck and shoulders it delivers the right amount of pressure for optimal relaxation Whether you seek relaxation or relief from muscle tension this personal massager is sure to enhance your overall well-being but the Breo N5 Mini boasts two massage modes This delivers a customized and therapeutic experience that caters to individual preferences and specific needs I enjoyed the kneading and tapping massage which soothed my sore muscles and helped me unwind after a long day while I opted for the lower intensity level most of the time I did choose the higher intensity level if I had more tension to work out It’s not super easy to see the buttons while you use it But it’s easy enough to remember which button does what and feel them since they’re large Simply recharge it via the included USB cable when the battery runs low As this was my first-time using a personal massager My personal experience with the Breo N5 Mini has been nothing short of impressive As someone who carries stress in my shoulders I enjoyed the relaxation and relief this compact massager provided I found the kneading mode to be particularly effective for alleviating tension in my neck and shoulders was a rejuvenating choice for stimulating circulation and relieving muscle fatigue The device seamlessly combines relaxation and pain relief The deep-kneading and tapping motions promote muscle relaxation and stress reduction while the precise design allows for targeted pain relief in specific areas It’s proven to be an invaluable addition to my wellness routine and its effectiveness in promoting relaxation and soothing muscle aches has become an essential part of my daily self-care regimen The Breo N5 Mini boasts a user-friendly interface with intuitive controls I was impressed by and thankful for its straightforward nature The control panel is conveniently located within easy reach of your fingers so you can easily make mid-massage adjustments So switching between different massage modes and adjusting the intensity levels is a breeze Since Breo recommends not to use it for more than 10 minutes a day I found that it comfortably lasts through a week of regular use The battery indicator provides real-time feedback on the battery’s status Though it was my first time using a personal massager, I wholeheartedly recommend the Breo N5 Mini. Coming in at a reasonable price point of $139.99 I highly recommend this product to anyone seeking an effective way to relieve stress the Breo N5 Mini shines as an outstanding personal massager and effective performance contribute to its exceptional value Whether you’re new to personal massagers or a seasoned enthusiast you can use the code BRFLOW20 to receive 20% OFF sitewide The approval of the supplemental New Drug Application (sNDA) in patients aged ≥18 years was based on the results of a clinical trial of over 12,000 patients in 23 studies of patients aged ≥12 The FDA issued a complete response letter in regards to the proposed use of Breo Ellipta in patients aged 12–17 stating that additional data would be required to further demonstrate the safety and efficacy of the product in this population Breo Ellipta is a fixed-dose combination of the inhaled corticosteroid (ICS) fluticasone furoate and the long-acting beta2-agonist (LABA) vilanterol The combination inhaler works by decreasing inflammation in the lungs and helping the muscles around the airways of the lungs stay relaxed to increase airflow and reduce exacerbations in patients with asthma RELATED: First Breath-Actuated, Dry-Powder Inhaler for Acute Asthma Approved Breo Ellipta is already indicated for long-term maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema and to reduce exacerbations of COPD in patients with a history of exacerbations in patients aged ≥18 Breo Ellipta dry powder inhaler for asthma has been approved for 100mcg/25mcg and 200mcg/25mcg strengths For more information visit MyBreo.com The US Food and Drug Administration (FDA) has approved the combination of fluticasone furoate/vilanterol (Breo Ellipta GlaxoSmithKline/Theravance) for the once-daily treatment of asthma in adults aged 18 years and older Fluticasone furoate (FF) is an inhaled corticosteroid (ICS) and vilanterol (VI) is a long-acting beta2-agonist (LABA) The FDA approved two strengths (100/25 and 200/25 μg) for adults with asthma administered once daily using the Ellipta dry powder inhaler The efficacy and safety of FF/VI has been studied in more than 12,000 subjects in 23 studies of patients aged 12 years and older In March, a US FDA advisory committee recommended approval of Breo Ellipta in adults In a complete response letter related to the proposed use of Breo Ellipta in children aged 12 to 17 years the FDA said the data submitted do not show an adequate risk–benefit ratio to support the approval in children "The FDA stated that additional data would be required to further demonstrate the safety and efficacy in this population," GlaxoSmithKline and Theravance noted in an April 30 joint news release Breo Ellipta (FF/VI 100/25 μg) is already approved in the United States for long-term, once-daily, maintenance treatment of airflow obstruction and for reducing exacerbations in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema Breo Ellipta is not indicated for the relief of acute bronchospasm The prescribing information notes that LABAs increase the risk for asthma-related death and further advises only prescribe Breo Ellipta for patients not adequately controlled on a long-term asthma control medication or whose disease severity clearly warrants initiation of treatment with both an ICS and a LABA Once asthma control is achieved and maintained assess the patient at regular intervals and step down therapy (e.g. discontinue Breo Ellipta) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication Do not use Breo Ellipta for patients whose asthma is adequately controlled on low- or medium-dose ICS." Breo Ellipta is contraindicated for primary treatment of status asthmaticus or other acute episodes of chronic obstructive pulmonary disease or asthma for which intensive measures are required and in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to FF Breo Ellipta should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of chronic obstructive pulmonary disease or asthma or used for the relief of acute symptoms; that is as rescue therapy for the treatment of acute episodes of bronchospasm Acute symptoms should be treated with an inhaled Complete prescribing information and a medication guide are available at on the GlaxoSmithKline website Medscape Medical News © WebMD, LLC Heartwire © WebMD, LLC WebMD Health News © WebMD, LLC Reuters Health Information © Send comments and news tips to news@medscape.net MedscapeDisclosure: Megan Brooks has disclosed no relevant financial relationships Click the topic below to receive emails when new articles are available You will receive email when new content is published GlaxoSmithKline's Relvar Ellipta was approved by the EMA for asthma and COPD The overall market is expected to continue to grow but an NIH study indicates more patient conversations need to happen GlaxoSmithKline expanded its COPD reach in Europe. The company announced Monday that the European Medicines Agency Committee for Medicinal Products for Human Use—familiarly known as EMA CHMP—approved the company’s Relvar Ellipta for chronic obstructive pulmonary disease (COPD) and asthma. The FDA approved this same drug in May under the name Breo Ellipta The market is an attractive one. GBI Research projected in October that the global COPD market is worth around $11.3 billion, and could hit $15.4 billion by 2019. Further, the drugs are hard to copy. Despite going generic, GlaxoSmithKline’s Advair Diskus remains a strong competitor because the inhaler is difficult to replicate Boehringer Ingelheim VP of Respiratory Marketing Burcu Erylimaz told MM&M that her company—known in the COPD space where it co-markets Spiriva with Pfizer—is intent on deepening its respiratory presence in asthma and idiopathic pulmonary fibrosis and that while inhalers can be difficult to duplicate complexity is not the overriding factor when it comes to developing a delivery system inhaled drugs are not as vulnerable to being generalized as pills are.” US estimates put the COPD patient headcount at around 24 million and the National Institutes of Health data indicates it is now the third leading cause of death in the US Yet a recent NIH study shows that the patient pool may in fact be much larger The US agency released a survey in November that showed that while the breath-taking condition is most commonly associated with smokers 1 in 6 COPD patients are not current or even former smokers The NIH also found that 26% of patients who have COPD symptoms wheezing or shortness of breath—don’t tell their doctors BI’s patient research may explain some of the government’s findings Erylimaz says former smokers tend to feel “I did this to myself.” BI’s focus groups with asthma patients also show how patients cope with respiratory illnesses and avoid treatment “It is very interesting to see that they kind of make their life smaller so they can make room for asthma and say ‘I’m fine The NIH’s findings also show that it’s not just patients who are ignoring COPD Researchers said healthcare providers also missed opportunities to talk with patients about the condition Join us for the fifth annual Pinnacle Awards program, which celebrates the medical marketing industry’s most venerable marketers, strategists and creators. Get to know each of these companies by learning about their culture How artificial intelligence can deliver more meaningful business outcomes for marketers advertisers can achieve big lifts in awareness and sales of their medications among all demographics In a world where healthcare is moving fast HCG is spearheading the charge to turn scientific potential into real-world impact Register for free and enjoy unlimited access to: The US Food and Drug Administration has ruled that GlaxoSmithKline may remove boxed warning labels from several inhaled corticosteroid/long-acting beta2 agonist (ICS/LABA) combination medications according to a press release.1 Warnings and Precautions labeling for ICS/LABA-class medications was also updated The list of medications includes Breo Ellipta® (fluticasone furoate/vilanterol) Advair® Diskus (fluticasone propionate/salmeterol) The FDA decision follows review of data from 4 randomized controlled safety trials two of which were submitted by GlaxoSmithKline The first trial (AUSTRI, SAS115359; ClinicalTrials.gov Identifier: NCT01475721) was a 26-week study of controller treatment in adolescents and adults with asthma Researchers sought to determine if LABA plus ICS therapy was noninferior to ICS therapy alone concerning the risk of a composite of several serious adverse events Full study results were published in The New England Journal of Medicine.2 The second trial (VESTRI, SAS115358; ClinicalTrials.gov Identifier: NCT01462344) also examined if the addition of LABA to ICS therapy is noninferior to ICS therapy alone in patients between 4 and 11 years of age Primary analyses included the risk of a composite of serious asthma-related adverse events Full study results were also published in The New England Journal of Medicine.3 The most common adverse reactions associated with Advair Diskus and HFA include upper respiratory tract infection The most common adverse reactions associated with Breo are nasopharyngitis You’ve viewed {{metering-count}} of {{metering-total}} articles this month Don’t miss out on today’s top content on Pulmonology Advisor Register for free and gain unlimited access to: Canadian regulators have approved the dry powder combination of fluticasone furoate and vilanterol (Breo Ellipta, GlaxoSmithKline/Theravance) for once-a-day treatment of asthma in adults with reversible obstructive airways disease Health Canada approved two strengths of FF/VI (100/25 and 200/25 μg) for the new asthma indication The drug is not indicated for patients whose asthma can be managed with low- or medium-dose inhaled corticosteroids; occasional use of a rapid-onset inhaled beta-agonist; or a combination of the two therapies increase the risk for asthma-related death Clinical trial evidence also suggests LABAs boost the chances of asthma-related hospitalization for children and adolescents clinicians should only prescribe VV/FI for patients who cannot adequately control their asthma with a long-term medication such as an inhaled corticosteroid or whose disease severity warrants both an inhaled corticosteroid and a LABA Clinicians should regularly assess the patient once he or she achieves and maintains asthma control The FDA gave FF/VI a green light for asthma in April Robert Lowes is a journalist for Medscape Medical News A former senior editor at Medical Economics magazine and contributor to numerous healthcare publications Robert has covered medicine from almost every conceivable angle — public policy His articles have won major awards such as first place in the annual journalism competition of the National Institute for Health Care Management and several have been republished in books He can be contacted at rlowes@medscape.net Propeller Health recently announced that its Propeller platform has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for use with Breo Ellipta entered into a research and development agreement that led to the creation of the sensor for Breo Ellipta “We are pleased to announce the FDA clearance of the Propeller platform for use with GSK’s Ellipta inhaler,” David Van Sickle, Propeller’s co-founder and CEO, said in a press release “Inclusion of GSK’s Ellipta inhaler in Propeller’s digitally-guided therapy platform is an important step in our goal of modernizing the management of respiratory disease.” Van Sickle said Propeller will be working closely with GSK to deploy sensors for the Ellipta inhaler in the U.S the Propeller platform has been used by patients with chronic obstructive pulmonary disease (COPD) and asthma in 45 commercial programs nationwide Propeller aims to help patients and their physicians improve COPD and asthma standard of care as well as improve the symptoms and outcomes of these chronic diseases The FDA clearance follows CE Mark and Health Canada registration for the Propeller platform and system earlier this year and marks the eighth time the FDA has cleared a Propeller product nationally and internationally Breo Ellipta inhalation powder contains a combination of fluticasone (a steroid) and vilanterol (a bronchodilator) It prevents the release of substances in the body that cause inflammation and relaxes the muscles in the airways in order to improve breathing Breo Ellipta is to be used once-daily by COPD and asthma patients to help improve symptoms and prevent bronchospasm or asthma attacks Breo Ellipta is indicated for long-term treatment the inhaler is a short-term therapy until symptoms are controlled with other medicines “While it is still in the early stages of development the emerging field of digital healthcare holds great promise for respiratory medicine,” said Dave Allen head of respiratory research and development at GSK “The approval of the Propeller platform for use with the Ellipta inhaler will help us understand how patients interact with the Ellipta inhaler accurately and in real-time.” “By exploring the benefits of sensor technology in this way we hope to gain valuable insights into usage patterns with the ultimate goal of driving improvements in patient care while reducing the complexity and cost of clinical trial,” Allen added The FDA’s 510(k) clearance permits the company to market the device using the 501(k) pathway which allows the FDA to determine whether the product is equivalent to other products before marketing approval Medical device manufacturers are required to submit a pre-market notification if they intend to introduce a device into commercial distribution for the first time or reintroduce a device that will be significantly changed or altered This site is strictly a news and information website about the disease This content is not intended to be a substitute for professional medical advice Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition Never disregard professional medical advice or delay in seeking it because of something you have read on this website Subscription boxes have become so ubiquitous — I pass by plenty on my building's doorstep each day.  there's a subscription box to match — but that doesn't mean they've lost their novelty entirely Subscriptions are still a fun way to discover cool and make life easier by having things you love sent to your door on a regular basis but rather just makes it its mission to help subscribers discover cool stuff Breo Box is a seasonal subscription box filled with five to eight useful interesting products curated for the season The products are packed into a durable wood box,  sent to your door every three months You can choose from either a seasonal or annual subscription of Breo Box Both deliver the same box at the same time (every three months) A seasonal subscription is paid out four times a year with each payment ranging between $139-$159 (some boxes are more expensive than others) or just skip a box if you don't want to receive one for any given season.  whether to try the service for yourself or gift to a friend the Spring 2020 box included a PhoneSoap Pro and more; the Winter 2019 included an Ekho HD Video Drone there was a card listing the products included and how much they would have cost if you chose to buy them individually The box contained five items: an Ehko Waterproof Camera Inventions Li'l Dipper (basically a heated mini ice cream scooper that can get through your rock-hard pint of Ben & Jerry's) Having only five products in the box was on the lower end of the spectrum especially considering all of the products are full-sized many of the products in the box weren't ones that I would use in my everyday life there were some I enjoyed using and probably wouldn't have discovered without Breo Box relatively small size (perfect for countertops) which lets you seamlessly store your concentrate in the fridge to keep it fresh.  but also because I probably never would have come across it on my own Dodow is a French company with a fresh take on sleep aids The one I got is a small device that uses a light system to help lull you to sleep Tap the Dodow lightly and it will project a pulsing light onto the ceiling The projected light will expand and retract over the course of either eight or 20 minutes (whatever you choose) By syncing your breathing with Dodow's pulsing light you bring your breathing rate down significantly ultimately slowing down your metabolism and helping you relax If your mind is racing with ideas and thoughts before bed focusing on this light is a simple way to slow everything down and help you fall asleep quickly.  it's worth considering that any of the products inside the box would make great individual gifts you may still get a relatively good value from it this is an easy but still creative option.  The downfall is sometimes you may not love all the products or want to use them at all If you can reconcile that idea with the price creative service that'll bring unique and interesting finds to your doorstep.  Results from a phase 3 trial evaluating Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol; GlaxoSmithKline) in patients with uncontrolled asthma showed that the single inhaler triple therapy provided a significant improvement in lung function when compared with Breo Ellipta (fluticasone furoate/vilanterol; GlaxoSmithKline) Trelegy Ellipta is currently approved by the Food and Drug Administration (FDA) for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations In the CAPTAIN (Clinical study of Asthma Patients receiving Triple therapy through A single INhaler) study patients whose asthma was inadequately controlled despite treatment with inhaled corticosteroid (ICS)/long-acting beta-2 agonist (LABA) maintenance asthma medication were randomized to receive Trelegy Ellipta or Breo Ellipta once daily Patients were assigned to 6 different treatment arms: Trelegy Ellipta 100/31.25/25 The primary endpoint of the study was change from baseline in trough forced expiratory volume in 1 second (FEV1) at 24 weeks; annualized rate of moderate/severe asthma exacerbations was designated as a secondary endpoint the study investigated 2 additional doses of Trelegy: 100/31.25/25mcg and 200/31.25/25mcg; increases in trough FEV1 were found to be of similar magnitude to those seen with the 100/62.5/25mcg and 200/62.5/25mcg doses data will be submitted for regulatory review to the FDA for a potential asthma indication once the full dataset is available For more information visit gsk.com This article originally appeared on MPR the content you were looking for was not found Sorry, we couldn’t find that content. We suggest you start with our Home Page At IPWatchdog.com our focus is on the business policy and substance of patents and other forms of intellectual property Today IPWatchdog is recognized as the leading sources for news and information in the patent and innovation industries Images on IPWatchdog Primarily Provided by Our website uses cookies to provide you with a better experience. Read our privacy policy for more information.Accept and Close After working as part of the editorial team for Medical News Today Markus wrote a large body of medical information articles for our Knowledge Center he has qualifications in medical science and science communication and enjoys photography Dr. Raj Dasgupta is an ABMS quadruple board certified physician specializing in internal medicine He practices at the University of Southern California where he is an associate professor of clinical medicine assistant program director of the internal medicine residency program and the associate program director of the sleep medicine fellowship Dasgupta is an active clinical researcher and has been teaching around the world for more than 18 years Beth lives in London and works as a freelance writer on a range of projects Along with writing regular articles for Medical News Today This involves recording minutes for conferences and documenting their process of curating art exhibitions She earned her undergraduate degree at West Chester University in Pennsylvania and is completing her master’s degree at Dartmouth College in Hanover Lindsey runs a successful content marketing business and works with clients all over the world to create content that shines for blogs She is a voracious reader and insatiable traveler and spending quality time with family and friends Zia Sherrell is a health copywriter and digital health journalist with over a decade of experience covering diverse topics from public health to medical cannabis Her mission is to empower and educate people by bringing health matters to life with engaging Zia enjoys traveling and chasing after her dogs Bronchodilators and lifestyle measures can help manage it A person with COPD may have chronic bronchitis, emphysema These issues limit the functioning of the airways and cause trouble breathing People with COPD may also have a higher risk of severe COVID-19 symptoms. Learn more here. Someone with COPD may have one or both of these issues and the severity of each varies from person to person Emphysema damages the air sacs of the lungs The lungs lose their elasticity and are no longer able to exchange oxygen and carbon dioxide efficiently Chronic bronchitis involves inflammation of the lining of the airways This results in increased production and thickening of mucus Bronchitis becomes chronic when it persists and resists treatment Asthma symptoms may be part of COPD, and a history of asthma can increase the risk of developing the condition which spasm and overreact to inhaled substances COPD is a lifelong issue involving irreversible damage to the lungs and worsening difficulty breathing and airway obstruction A person with advanced COPD may be unable to climb the stairs or cook They may need medications and supplementary oxygen In 2014, COPD was the third leading cause of death in the United States A person with severe symptoms may also have: Anyone with any severe symptoms should receive immediate medical care If symptoms are mild, a person may not realize that they have COPD. Almost 6.4% of the U.S but its actual prevalence may be far more extensive Here, find tips to stop wheezing. Explore it with the mouse pad or touchscreen In the U.S., as many as 75% of people with COPD smoke or once did there is usually an underlying health issue Asthma can increase the risk of COPD because it inflames and narrows the airways treatment can usually reverse any damage resulting from asthma Various conditions can cause coughing and breathing problems these symptoms persist and worsen over time To identify COPD measures the amount and speed of airflow during a short breath The person blows hard into a tube attached to a device called spirometer This and similar tests can help rule out other conditions or indicate COPD The doctor will also use the Global Initiative for Chronic Obstructive Lung Disease guidelines to assess COPD symptoms and the risk of them worsening Treatment involves managing the symptoms to improve the quality of life and slow the progression of the health issues involved Quitting smoking can help improve COPD symptoms and slow its progression Here, learn about managing nicotine withdrawal. Whenever possible, people should reduce their exposure to air pollutants Medications can help manage COPD symptoms and prevent complications To help ease breathing, a doctor may prescribe an inhaler that contains a number of drugs. For example, to relax the muscles around the airways and make breathing easier, an inhaler may contain a medication called a bronchodilator An inhaler may also contain a glucocorticoid, a type of corticosteroid that can reduce inflammation in the airways They act quickly and are effective for a few hours They can make breathing easier during a COPD flare-up the doctor may adjust the medication regimen to help control worsening symptoms and flare-ups They may also recommend antibiotics to manage any acute bacterial infection that develops, as well as vaccination to ward off the flu and pneumonia A person with COPD who has effective inhaled treatment may still experience reoccurring flare-ups that require hospital care the doctor may recommend the oral anti-inflammatory medication roflumilast (Daliresp) or the oral antibiotic azithromycin (Zithromax) to reduce the frequency of flare-ups.Doctors largely base their choice on anticipated side effects as researchers have yet to directly compare the efficacy of the two medications Learn more about how to manage a COPD flare-up. which involves breathing oxygen through a device — a mask or nasal prongs — attached to a tank either continuously or only at certain times of the day Some procedures that may be an option for certain people with COPD include: A surgeon needs special training and equipment to place endobronchial valves Various measures can help reduce the impact and progression of COPD These can counter breathlessness, and some examples include pursed-lip breathing and diaphragmatic breathing Here, learn other techniques to relieve shortness of breath. Pulmonary rehabilitation aims to help people maximize their activity levels and quality of life Here, find other natural ways to manage COPD symptoms. People with COPD are more likely to experience: Following up with the healthcare team and attending all medical appointments can help prevent or manage complications COPD can be life-threatening, and a person’s life expectancy largely depends on whether they smoke and the severity of existing lung damage People who smoke and have advanced COPD may lose around 6 years of their life expectancies apart from the 4 years that smoking itself takes away and people who smoke can reduce their risk by quitting as soon as possible COPD is an irreversible lung condition that causes difficulty breathing Someone with COPD may have chronic bronchitis but treatment can help manage the symptoms and enhance the quality of life Anyone who receives a COPD diagnosis should take action to protect their lungs Find more tips for preserving lung health here. we are committed to developing the next generation of leaders in biomedical research We provide top quality education and training and an invigorating scientific atmosphere that equips our trainees with the tools to tackle the challenges of tomorrow Embedded within the Health Sciences Office of the AVP for Research the Biomedical Research Education Office (BREO) aims to foster an exceptional training environment rooted in evidence-based practices and a holistic approach that equips our trainees with the tools to tackle the biomedical challenges of tomorrow and the skills to identify and obtain fulfilling careers in science At U of U Health, we invest in the next generation of scientific leaders as much as we do in our cutting-edge research We have an extraordinary number of outstanding research graduate programs You can choose from interdepartmental programs in addition to our department PhD Postdoctoral fellows enrich the robust research enterprise at the University of Utah We place a high value on your deep expertise and the contributions you will make while you train with us Our focus is to connect you with the abundant resources at your disposal to become a successful The Biomedical Research Education Office provides services and resources to support faculty as they develop T32 applications and administer funded research programs there are a number of administrative tasks that need to be completed to ensure compliance with NIH and maintenance of benefits at the university The Biomedical Research Education Office provides services and resources to support the Training Grant Community navigate this process Resources are available for trainees and administrators The Biomedical Research Education Office is committed to offering graduate students and post-baccalaureate participants rigorous curriculum and active guidance so that they can accomplish professional growth and successful careers in the field of biomedical sciences recognized for his research on cell growth and proliferation was elected to the prestigious National Academy of Sciences for his pioneering work and contributions to science Trained and genetic differences could help the women survive the intense physiological stresses of free-diving—and could ultimately lead to better treatments for blood pressure disorders Disease modeling research suggests that for some cholera outbreaks prescribing antibiotics more aggressively could slow or stop the spread of the disease and even reduce the likelihood of antibiotic resistance A team of researchers has used advanced DNA sequencing to develop the most comprehensive atlas yet of genetic change through generations laying the foundations for new insights into the roots.. Research in the Sundquist lab laid the foundations for the development of lenacapavir a drug that prevents HIV infection with 99.9% to 100% efficacy and could dramatically lower infection rates.. leadership is actively advocating for research and planning strategically for the future We have developed guidelines and a worksheet to help researchers who have received.. A new workshop series will focus on how to talk and post about research for broad audiences Leading scientists joined forces to explore how the microbes that live in and on our bodies can be leveraged to provide real-world solutions and improve health care one of the most contagious hospital-acquired infections spreads more than three times more than previously thought What if buildings could be made smarter and more sustainable by engaging with their occupants Changing colors indicate energy usage. Image © Bruce DamonteGoing beyond the concept of smart buildings the project leverages human intelligence by creating a responsive system that communicates real-time resource usage The system equips buildings with “express” data from building electrical and audiovisual systems through sensory outputs Bridging the gap between building systems and their occupants BREO assures that people are not only aware of their environmental impact but are also empowered to make changes The system leverages human senses to communicate resource benchmarking ensuring occupants can readily discern whether the building is in a positive or negative state about its resource usage While the project is still in the research phases it has seen promising prototypes that seek to enhance occupants' relationships with buildings Related Article Energy Efficiency Now Offers a Technical Justification for Colors The sensory technology used in the BREO project represents a significant departure from the current approach to building management. Going beyond efforts of greening buildings, BREO views sustainable development in a more holistic light. The occupants of a building are a key factor in the broader system of building design. The human "hive mind" is pivotal in fostering sustainability and solving wicked problems related to climate change.  This article is part of the ArchDaily Topics: Decarbonize Architecture presented by Holcim This series explores how cities of the future can be low-carbon Every month we explore a topic in-depth through articles, interviews, news, and architecture projects. We invite you to learn more about our ArchDaily Topics. And, as always, at ArchDaily we welcome the contributions of our readers; if you want to submit an article or project, contact us You'll now receive updates based on what you follow Personalize your stream and start following your favorite authors If you have done all of this and still can't find the email In Asthma, News GlaxoSmithKline (GSK) and VIBATIV® (telavancin) developer Theravance Biopharma have just been granted Canadian approval for Breo Ellipta a once-a-day maintenance treatment for asthma in patients who are at least 18 years old and have reversible obstructive airways disease delivers a fixed-dose combination of inhaled corticosteroid fluticasone furoate and long-acting beta2-agonist (LABA) vilanterol BREO® ELLIPTA® was also approved in Canada as a maintenance treatment for airflow obstruction in patients with COPD Breo Ellipta will soon be available as an asthma treatment in the country in two dosages: 100/25mcg and 200/25mcg GSK Canada country medical officer Sally Taylor said a GSK asthma treatment approved in Canada now provides physicians with a once-daily treatment option delivered via the Ellipta inhaler to meet the needs of appropriate adult patients.” Theravance president and chief executive officer Michael Aguiar said: “With today’s approval of Breo Ellipta in Canada we are pleased to expand the number of patients able to benefit from this important medicine As a once-daily ICS/LABA treatment for adults with asthma people suffering from this chronic condition now have an additional option.” RELVAR®/BREO® ELLIPTA® has been approved in 58 countries for marketing and has been launched in 36 countries as of December 31 In other recent asthma news, a study recently published in the journal Annals of Allergy, Asthma and Immunology showed that inhaled tiotropium is a safe and effective therapy for adolescents with moderate to severe asthma The study conducted by researchers at the Hospital Central de las Fuerzas Armadas in Uruguay and the Pontificia Universidad Católica de Chile in Chile and is entitled “Tiotropium for the treatment of adolescents with moderate to severe symptomatic asthma: a systematic review with meta-analysis.” Researchers found that tiotropium therapy was associated with a significant improvement in FEV1 in comparison to patients under a placebo treatment tiotropium was also found to reduce the number of patients experiencing a worse asthma exacerbation or episode and also the number of patients with at least one exacerbation in comparison to patients in the placebo group The team found no significant differences between tiotropium therapy and placebo in terms of rescue medication use Tagged , , , , You must be logged in to post a comment The deal hints at new threats to GSK's respiratory portfolio which also faces challenges from brand-name rivals and pricing pressures Hikma said it will work with Vectura on at least three generic versions of Ellipta products while development of the Open-Inhale-Close dry power inhaler could yield copies to as many as five GSK medicines Ellipta products are a core part of GSK's respiratory business, earning nearly a third of the pharma's total sales for the segment during the third quarter Breo Ellipta (fluticasone furoate/vilanterol) — sold as Relvar Ellipta in other markets — is the largest product of the five marketed Ellipta products Company executives are already warning investors that Breo is the most vulnerable of the Ellipta products when generics to Advair (fluticasone/salmetrol) enter the market currently GSK's top-selling respiratory drug have fallen steadily in recent quarters and are expected to tumble further with generic competition Hikma has attempted to win approval of a generic Advair copy before, only to have the Food and Drug Administration reject its application The threats have GSK focusing more on its biologic Nucala (mepolizumab) as well as its newly approved three-in-one inhaler Trelegy Ellipta (fluticasone fuorate/umeclidinium/vilanterol) Get the free daily newsletter read by industry experts Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy spurring a wave of research practically overnight and research into drugs that might treat it draws scant funding — problems that have deep roots The free newsletter covering the top industry headlines — The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis The FDA late Monday approved sales of Trelegy Ellipta developed jointly by GlaxoSmithKline PLC and Innoviva Inc It contains three widely used types of medicine to prevent — rather than treat —flare-ups of the life-threatening breathing disorders patients inhale the medicines through their mouth to open breathing passages and reduce inflammation that can make breathing difficult in people with chronic obstructive pulmonary disease requiring patients to add more medicines to prevent flare-ups that can land them in the emergency department — or worse Many patients use two inhaler types plus other medicines An estimated 384 million people worldwide have chronic obstructive pulmonary disease which can make everyday activities such as walking up stairs difficult It's usually caused by cigarette smoking or exposure to secondhand smoke chemical fumes or excess dust in the environment U.K.-based GlaxoSmithKline is launching Trelegy with a list price of $530 per month That's $146 a month cheaper than the combined prices of two GlaxoSmithKline inhalers that together contain the same three medicines: Incruse Ellipta and Breo Ellipta The medicines are an inflammation-reducing steroid called fluticasone furoate drugs that widen narrowed airways and relax their muscles Common side effects include headaches and other pain Vilanterol and similar drugs carry an increased risk of asthma-related death Trelegy also can worsen glaucoma and certain infections Insurers and prescription benefit managers likely will win significant discounts off the $530 retail price in exchange for covering Trelegy those payers may pass all or much of the savings on to employers and other clients rather than reducing patients' out-of-pocket costs should help the company rebuild its flagship respiratory medicine business thanks to its widely used allergy drug Flonase and its Flovent and Advair inhalers and the drugmaker now sells a nonprescription version which provided about one-third of Glaxo's revenue for many years also has seen increasing competition in recent years Advair sales are down by more than half since their peak of $8.15 billion in 2011 and are expected to decline to just $1.43 billion by 2020 and the Anoro inhaler launched in 2013 have barely made up for one-sixth of that lost  UK pharma major GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) today announced that Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for chronic obstructive pulmonary disease (COPD) is available to US pharmacies Breo Ellipta was cleared for marketing earlier this year by the US Food and Drug Administration and has been hailed as having blockbuster potential with peak sales estimates of as much at $4 billion The drug is a combination of the inhaled corticosteroid (ICS) fluticasone furoate and the long-acting beta2-agonist (LABA) vilanterol maintenance treatment of airflow obstruction in patients with COPD It is intended to reduce exacerbations of COPD in patients with a history of exacerbations TwitterLinkedin Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze This slideshow reviews drug information for BREO ELLIPTA (fluticasone furoate, vilanterol). Click here for the complete BREO ELLIPTA new product monograph the heating panel promotes blood circulation for relaxing warmth the Breo iSeeM has a concave curved surface to protect and pamper the eyeballs and provide maximum comfort And the seal allows you to adjust the fit to suit your face shape the elastic hand hugs every head shape and size so you can take it on the go and store it conveniently Like James Brown's "brand new bag," the Berklee Really Eclectic Orchestra (BREO) brings something innovative to the musical scene: a chance for young string players to get together and explore contemporary pop styles, such as jazz, funk, rock and fusion. Founded last fall by Arlington resident and Berklee associate professor Mimi Rabson BREO is an ensemble for Boston-area high school students who want to learn how to improvise and perform in a variety of musical genres decided she wanted to play pop music at a fairly young age "When I was in high school," Rabson recalled "I found there was this big disconnect between the music I was doing for my lessons and the music I listened to at home for fun I knew there was no clear path to where I wanted to go Rabson's older sister, Ann, who had launched a successful career as a blues musician, bought Rabson her first jazz album, as well as recordings featuring violinists Papa John Creach and Don "Sugarcane" Harris "That gave me the idea that it's possible to play different kinds of music on the violin," Rabson said To join BREO, send an e-mail to PerformanceDivision[@]berklee.edu with the subject line "RSVP for BREO Jam" or call 671-747-6276. For more information, visit www.berklee.edu/BREO or use the above e-mail address While at New England Conservatory (NEC), a friend of Rabson's who was a jazz saxophone player introduced her to the Real Book, the standard compendium of jazz tunes, and explained how to use it. "That opened up a bunch of doors," she noted. Also while at NEC Rabson became one of the founding members of the Klezmer Conservatory Band  "What I loved about that was that I could play with a drummer It was great to be able to do it," Rabson said "I have nothing against classical training; I'm grateful for it and all string players should have it," Rabson asserted "but it's nice to have some alternatives and be trained in those alternatives it's difficult for string players to get that kind of training In BREO there's no sheet music; everything is learned by ear  "We're lucky that there's a way to preserve music in written form," she noted "but if composers of the past had been able to make recordings on their phones I wonder whether we would have written music." "there's a lot of stuff you can't write down the way written music is played depends on the person reading it "Classical musicians are trained to read notes and make a specific sound," Rabson said "but someone who's had jazz training will look at the same exact notes and rhythms Notes on the page are really a small part of what's in the music." may be concerned that playing pop or jazz may have a negative effect on their classical technique "Even in the world of classical music," she said "you use different techniques for playing Renaissance People play in a variety of styles every day They're not mutually exclusive; they're complementary Rabson mentioned that a number of classically trained violinists "They play in lots of styles," Rabson said Having run a similar ensemble for Berklee College students for the last 15 years and one for the Berklee Five-Week Summer Performance Program for half a decade Rabson sees BREO as a natural outgrowth of that experience "Berklee is the only place to do this," Rabson said thanking the administrators who have supported her in developing the idea vice president of special programs; Matt Marvuglio dean of the Professional Performance Division; David Wallace chairman of the String Department; Krystal Banfield dean of Berklee City Music; and Robert Doezema and John Pierce associate directors of the Five-Week Performance Program "I'd like to see this model spring up in other music programs and have other teachers doing it she would like to have several BREO ensembles at different levels and they're scheduled on Friday nights so they don't conflict with Boston Youth Symphony Orchestras or NEC Prep offerings (See sidebar for information about how to join.) I was nervous when I first tried to improvise but now I can do it fluently in three keys." Zhu concurred: "BREO lets us think creatively You get to meet a lot of new people from all around Boston and you can just chill out and jam with them." Arlington High School instrumental music director Sabato ("Tino") D'Agostino also thinks highly of what BREO has to offer "The contrast among genres is helpful for students," he said "By widening their repertoire of music and techniques They're adding something to their vocabulary; it's like learning a new language." I've been looking for ways to connect different genres of music with my instrument," Rabson observed Many professional musicians have told me they wish they’d had a similar ensemble when they were in high school There's no reason to be a musician if you don't love it." This story by YourArlington feature writer Carla DeFord was published Thursday YourArlington is a 501(c)(3) nonprofit.Your contributions are tax-deductible  yourArlington.com • Massachusetts residents report about their town Liebling: "Freedom of the press belongs to those who own one." | Copyright © 2006-2025 site design: msgdesign.org Support Turkey Earthquake Emergency Relief Retailers are expanding their horizons in China by reaching into new categories and extending product lines to increase selection In preparation for this year’s 6.18 Mid-Year Shopping Festival, brands tapped consumer insights from Alibaba Group’s product development arm Tmall Innovation Center (TMIC) “There’s a limit in trying to reach new customers in the competitive retail environment in China because most of the consumer segments have been covered,” said Xie Wei Tmall Industry Development and Operation Center Large consumer goods companies spend an average of $1.4 billion in research and development (R&D) each year to bring new products to market, or 2-3% of their net sales, according to research by consulting group Bain & Company product innovations may account for up to 30% of their resources When British multinational Unilever worked with Alibaba to co-create products for China it leaned on Tmall’s data center to mine consumer insights discover innovative technology and understand relevant trends in the market the partners launched a brand called Purify and tested it with a small run to around 10,000 consumers then tweaked aspects such as packaging ahead of scaling production “It really depends on the partner and their ability and appetite to co-create and launch products together – that’s where the joint value creation comes from,” said Claire Hennah, Beauty & Wellbeing Chief Customer & Digital Officer at Unilever at the ShopTalk conference in London the co-created product stalled as Covid hit and slowed demand in China and the partners decided that the timing was not right “The best partnerships have been when it is a partnership That includes knowing when something doesn’t work,” said Hennah “That’s an example of trust on both sides.” New product launches can be risky, so when brands want to take the leap, TMIC’s artificial intelligence-powered Knowledge Hub is critical to pinpointing consumer demands “The data-driven approach helps set a clear goal for our R&D making it much faster for us to launch a new product,” said Jennifer Liu e-commerce general manager at Chinese wellness retailer Breo Breo has created a handful of eye-area massage devices but sales hit a ceiling a few years after launch the brand refined its scope to target young female consumers They often buy eye massage gadgets but use them infrequently because they are concerned about their makeup smudging TMIC’s data analytics suggested pivoting from eye area massaging to eye hydration an area that is growing in demand with prolonged computer and cellphone use among young office workers The device should also not ruin their makeup Breo quickly acted on this and in April launched a glass-like wearable that releases hydrating mist to calm and sooth It sold more than 5,000 units in four days and ranked as the top eye device for 6.18 presales between May 31 and June 3 consumers are eager to try new products and new ways of buying This attitude is most prevalent among the fast-growing cohort of Generation Z consumers, who are most likely to “buy products on the go,” according to consultancy McKinsey and TMIC supports this effort by cutting the average product incubation time from 18 months to just six “Consumer demands in the market change fast If it takes around a year for a product to launch trends would have changed by then,” said Xie Brands stuck in this rut risk missing out on evolving consumer tastes and behaviors TMIC’s more streamlined and data-driven development process helped Breo launch its latest eye massager in half the time The consumer-driven way of product innovation brings brands more certainty in growth and it also pushes brands for a digital upgrade of their company structure and supply chain TMIC has helped more than 2,500 brands accelerate their research and development processes Stay updated on the digital economy with our free weekly newsletter It is not indicated for relief of acute bronchospasm or for the treatment of asthma," the company said in a news release.  The FDA first approved Trelegy Ellipta in September 2017 for the long-term once-daily maintenance treatment of COPD patients who are receiving Breo Ellipta (fluticasone furoate/vilanterol) and require additional bronchodilation or who are receiving Breo Ellipta and Incruse Ellipta (umeclidinium) Approval for the expanded indication is based on data from Informing the Pathway of COPD Treatment (IMPACT) study involving more than 10,000 patients The study found that Trelegy Ellipta was superior to Breo Ellipta and Anoro Ellipta (umeclidinium/vilanterol) on multiple clinically important endpoints including reducing exacerbations and improving lung function and health-related quality of life "Up to half of patients with COPD on maintenance therapy will have experienced at least one exacerbation in the past 12 months so gaining an indication that reflects the role Trelegy Ellipta can play in reducing this risk is important," Ted Witek "We welcome this regulatory update which will allow physicians to offer the benefits of once-daily single inhaler triple therapy to appropriate patients with COPD." Full prescribing information for Trelegy Ellipta is available online For more news, join us on Facebook and Twitter US pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) have submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration for a fixed dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2 agonist vilanterol (FF/VI) as a once-daily treatment for asthma in patients aged 12 years and older The sNDA is seeking approval for two dose regimens Today’s filing is based on data generated from the comprehensive clinical development program for FF/VI in asthma The clinical development program comprised 48 clinical pharmacology studies in 1,328 subjects and 23 clinical studies in 12,051 patients with asthma including the Phase III efficacy and safety study of FF/VI reported in December 2013 All 5 Releases